Advance | $8,550,000 | (Feb 6, 2026)
Turnstile | $29,000,000 | (Feb 6, 2026)
Accrual | $75,000,000 | (Feb 6, 2026)
Certified by Founder
Lodge
Synnovation Therapeutics
start up
United States
- Wilmington, DE
- 18/01/2024
- Unknown
- $70,000,000
Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers.
We are dedicated to the discovery and development of first-in-class and best-in-class therapeutics that can improve the lives of people with cancer. Leveraging our deep expertise in medicinal chemistry, cancer biology and patient-focused precision medicine, we are building a diverse pipeline of novel small molecule targeted therapies. Our mission is to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.
- Industry Pharmaceutical Manufacturing
- Website https://www.synnovationtx.com/
- LinkedIn https://www.linkedin.com/company/synnovationtx/about/
adaption | $50,000,000 | (Feb 6, 2026)
Nixtla | $16,000,000 | (Feb 6, 2026)
Fundamental | $255,000,000 | (Feb 6, 2026)
Duna | $35,365,500 | (Feb 6, 2026)
Flock AI | $6,000,000 | (Feb 6, 2026)